Skip to content

Effectiveness of transcutaneous electrical acupoint stimulation combined with metoclopramide for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic laparoscopic surgery: a randomized, double-blind controlled trial

Effectiveness of transcutaneous electrical acupoint stimulation combined with metoclopramide for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic laparoscopic surgery: a randomized, double-blind controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087428
Enrollment
Unknown
Registered
2024-07-26
Start date
2024-04-08
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine fibroids, adenomyosis, endometriosis

Interventions

Group A: control group (Sham TEAS + saline) :30 minutes before induction of anesthesia, 1 day and 2 days after operation, the dominant side of Neiguan and He were selected. Sham TEAS ( target acupoin
Group B: drug group (Sham TEAS + metoclopramide):30 minutes before induction of anesthesia, 1 day and 2 days after operation, the dominant side of Neiguan and He were selected. Sham TEAS ( target acu
Group C: combination group (TEAS + metoclopramide):30 minutes before induction of anesthesia, 1 day and 2 days after operation, the dominant side of Neiguan and He were selected. TEAS was performed a

Sponsors

The First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1: Patients undergoing elective gynecological laparoscopic surgery 2: Age : 18-65 years 3: BMI:18 .5-28Kg / m^2 4: ASA grade I-II 5: Signing informed consent

Exclusion criteria

Exclusion criteria: 1: Pregnancy or Lactation 2: For those who are allergic or intolerant to the study drugs 3: There are ulcers or infections around the target acupoints 4: Nausea, vomiting or both within 24 hours before operation 5: Patients who used opioids, glucocorticoids, emetics or antiemetic drugs within 24 hours before surgery 6: People with vestibular disorders, neurological or psychiatric disorders, severe liver or kidney dysfunction 7: There is extravertebral motor disease 8: Participate in other researchers within 3 months

Design outcomes

Primary

MeasureTime frame
The incidence of postoperative nausea and vomiting within 24 hours after operation;Adverse events (treatment related/unrelated);

Secondary

MeasureTime frame
The incidence of PON, POV, PONV and severity of nausea and the number of vomiting/dry heaves were recorded for 0-2h, 2-6h, 6-24h, and 24-48h postoperatively.;Postoperative pain VAS scores, use of remedial antiemetic (ondansetron) versus opioids during the 48h postoperative period were recorded, and patient satisfaction was assessed after 48h postoperatively.;The operation time, anesthesia time, extubation time, recovery time, total hospital stay, intraoperative propofol dosage, remifentanil dosage, intraoperative bleeding, and fluid infusion were recorded.;Basic patient information was recorded: age, height, weight, BMI, smoking history, history of motion sickness/PONV, and type of surgery.;

Countries

China

Contacts

Public ContactLifeng Wang

The First Affiliated Hospital of Gannan Medical University

wwwanglifeng@126.com+86 135 7671 5202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026